We Venture Capital is the corporate venture capital arm of Werfen, a global leader in specialized diagnostics. It invests globally in early-stage diagnostics start-ups, digital solutions, and biotechnology in the diagnostics space, primarily at Series A.
36% of their portfolio is in Healthcare. Their most common stage is series-a (45% of deals). Average disclosed round size is $15.2M (across 5 rounds with reported amounts).
Portfolio
8
Fund Size
—
Top Stage
Series A
Last 12 Mo
0
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
11 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Respiree Pte Ltd | Series A | $11.6M | Jul 2025 |
 Portal Biotech | Series A | $35M | Jun 2025 |
 Deepull | Series C | — | Apr 2025 |
| DDEEPULL DIAGNOSTICS, S.L. | Series C | — | Apr 2025 |
| OOxford Cancer Analytics (OXcan) | Series A | $11M | Jan 2025 |
| Portal Biotech | Series A | — | Jan 2025 |
| Respiree Pte Ltd | Series A | $11.6M | Jan 2025 |
 Capitainer | Unknown | — | Feb 2024 |
 Proton Intelligence | Seed | $7.0M | — |
| Proton Intelligence | Pre-Seed | — | — |
| ZZetta Genomics | Seed | — | — |
Top Co-Investors
XYZ Venture Capital3 shared
8VC2 shared
WS Investment Company2 shared
Earlybird Venture Capital2 shared
SCVC2 shared
Amino Collective2 shared
British Business Bank2 shared
Pillar VC2 shared
SEEDS Capital2 shared
ClavystBio2 shared
Adaptive Capital Partners2 shared
Asabys Partners2 shared
UI Investissement2 shared
Kurma Partners2 shared
Columbus Venture Partners2 shared
Innovation Nest1 shared
Macmillan Cancer Support1 shared
OKG Investments1 shared
Cross-Border Impact Ventures1 shared
Civilization Ventures1 shared
Last updated: 20 October 2026